What Otsuka Pakistan does

Otsuka Pakistan Limited is a publicly listed Pakistani pharmaceutical company (Pakistan Stock Exchange ticker: OTSU) headquartered in Karachi with manufacturing operations in Hub, Baluchistan. Incorporated in February 1988 and commencing commercial production in September 1989, the company is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. (Japan), which holds 44.80% of shares alongside other Otsuka group affiliates (Otsuka Pharmaceutical Factory 13.14%, P.T. Otsuka Indonesia 9.95%), with the Feroz Family and general public holding the balance.

The company's primary business is the CGMP-compliant manufacture and sale of Intravenous (IV) solutions — including electrolyte solutions (RINGOLACT, PLABOLYTE-M, PLADEXSAL), carbohydrate solutions, and antibiotic infusions (OTSUFLOX). Beyond IV, it operates four additional product lines: therapeutic drugs (Pletaal/Cilostazol imported from Otsuka Korea for diabetic patients, Mucosta/Rebamipide for gastric ulcers — launched 2018); clinical nutrition (Aminoleban, AminoVel 600, Pan-Amin G, ProteN Gold, Fatolip, plus the newer Gen-DM MF, Neo-Mune, Once Dialyze); medical devices (UBiT Urea Breath Test for H. pylori diagnosis launched 2019, drug-eluting coronary stents and PTCA balloon catheters imported from Germany); and nutraceutical products (ORTie, AlphaBerry Plus) produced at a Nutraceutical Plant inaugurated in March 2023. Total issued capital is Rs.121 Million against Rs.200 Million authorized.

Revenue is generated through direct field sales to hospitals and clinicians across Pakistan via a field-manager and regional-sales-manager structure, supplemented by an exclusive distribution arrangement with Hospital Supply Corporation. No pricing is publicly disclosed. The company holds ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certifications as well as Drug Manufacturing License No. 000281, and participates in multiple industry associations (PPMA, KCCI, LCCI, HDAP, PCDA). It is led by CEO Mr. Moin ur Rehman (appointed February 2024) with Mr. Mikio Bando as Chairman of the Board.

Name

Otsuka Pakistan

Legal name

Otsuka Pakistan Limited

Website

https://otsuka.pk

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Otsuka Pakistan Limited is a Karachi-headquartered, publicly listed pharmaceutical manufacturer (PSX: OTSU) and indirect subsidiary of Otsuka Pharmaceutical Japan, producing CGMP-compliant IV solutions, clinical nutrition, therapeutic drugs, medical devices, and nutraceuticals for hospitals and clinicians across Pakistan.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC & Consumer Health Distributors (HLAIAJAC)

akta.pro secondary industries

Gastrointestinal & Digestive Health (HLAIADAD), Home Diagnostic & Self-Test OTC Kits (HLAIADAO)

Keywords

• Intravenous solutions
• Clinical nutrition
• Pharmaceutical manufacturing
• Medical devices distribution
• Therapeutic drugs

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Otsuka Pakistan generates revenue through the sale of pharmaceutical products including IV solutions, therapeutic drugs, clinical nutrition products, medical devices, and diagnostics. The company operates multiple product lines: IV solutions as primary business, therapeutic drugs (Pletaal, Mucosta) as second line, and medical devices including drug-eluting coronary stents as third line.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Otsuka Pakistan Limited manufactures and distributes pharmaceutical products including intravenous (IV) solutions, clinical and enteral nutrition products, therapeutic drugs, nutraceuticals, and medical devices. The company operates a cGMP-compliant manufacturing facility in Hub, Baluchistan for IV solutions and clinical nutrition, while importing therapeutic drugs and medical devices from Otsuka group companies. Products are marketed and sold in Pakistan through a direct field sales force and authorized distributors to hospitals, clinics, and healthcare professionals.

Product overview

Otsuka Pakistan Limited is a pharmaceutical company primarily focused on manufacturing Intravenous Solutions (IV Solutions) including Electrolyte Solutions, Standard Solutions, and Ampoules at its factory in Hub, Baluchistan. The company operates as a multi-segment business with four main product lines: (1) Intravenous Solutions - the core business including RINGOLACT, PLABOLYTE-M, PLADEXSAL, OTSUMOL, and OTSUFLOX antibiotic infusions; (2) Clinical Nutrition - including Aminoleban, AminoVel, Pan-Amin G, ProteN Gold, and Fatolip (20% Fat Emulsion in soft bag); (3) Therapeutic Drugs - imported from Otsuka Korea including PLETAAL for diabetic patients and Mucosta (Rebamipide) for gastritis/gastric ulcers; (4) Medical Devices - including UBiT Urea Breath Test for H. pylori diagnosis, drug-eluting coronary stents, PTCA balloon catheters, and angioplasty accessories; (5) Nutraceutical Products - including ORTie and AlphaBerry Plus; and (6) Enteral Nutrition - including Gen-DM MF, Neo-Mune, and Once Dialyze for specialized patient nutrition. The company is an indirect subsidiary of Otsuka Pharmaceutical Co. Ltd. Japan and maintains ISO certifications for quality, environment, and occupational health and safety.

Differentiator

Problem solved

Functional benefit

Products and services

• Intravenous (IV) Solutions A portfolio of large-volume intravenous solutions manufactured locally at the Hub, Baluchistan plant under cGMP standards, including RINGOLACT, RINGOLACT-D, PLABOLYTE-M, PLADEXSAL, OTSUMOL, OTSUFLOX, DEXOSAL, and other electrolyte, dextrose, and specialty solutions. Sold to hospitals and clinics in Pakistan for fluid and electrolyte therapy.
• Clinical Nutrition Products Parenteral and enteral clinical nutrition formulations including Aminoleban Oral, AMINOVEL 600, PAN-AMIN G, AMINOLEBAN Injection, PROTEN Gold, and Fatolip. Used by hospitals and clinicians for nutritional support of patients with hepatic, renal, and critical-care needs.
• Therapeutic Drugs
• Medical Devices and Diagnostics
• Nutraceutical Products
• Enteral Nutrition Products

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Eleven partnerships are on record, tiered strategic, core and minor.

• CIME-AKU (Aga Khan University)strategicStrategic or Co-development Partner · 27 May 2025Agreement Signing Ceremony between CIME-AKU and Otsuka Pakistan for collaboration in medical education and research initiatives.
• Hospital Supply CorporationcoreChannel Partner/ Reseller/ Distributor · 25 June 2018Exclusive distributor for Otsuka Pakistan products including Mucosta and medical devices. Handles distribution to hospitals and healthcare facilities.
• Otsuka Pharmaceutical Co. Ltd (Japan)coreOthersParent company and indirect subsidiary relationship. Otsuka Pharmaceutical Co. Ltd Japan is a multinational pharmaceutical company that completed 100 years of dedication towards improving healthcare in 2021. Provides licensing, technology, and guidelines for product manufacturing.
• Otsuka Pharmaceutical Factory, Inc. (Japan)coreOthersAffiliate company providing technical expertise and manufacturing guidance for IV solutions and pharmaceutical products. Contributes 13.14% to shareholding.
• P.T. Otsuka IndonesiaminorOthersAffiliate company within the Otsuka group. Contributes 9.95% to shareholding.
• Karachi Chamber of Commerce and Industry (KCCI)minorOthersIndustry association membership for business networking and advocacy.
• Lasbela Chamber of Commerce and Industry (LCCI)minorOthersIndustry association membership for business networking.
• Pakistan Pharmaceutical Manufacturers Association (PPMA)minorOthersTrade association membership for pharmaceutical industry representation.
• Pakistan Japan Business Forum (PJBF)minorOthersBilateral business forum facilitating Japan-Pakistan trade relations.
• Healthcare Devices Association of Pakistan (HDAP)minorOthersIndustry association for medical devices sector.
• Pakistan Chemists and Druggists Association (PCDA)minorOthersProfessional association for pharmacists and druggists.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Baxter International: Baxter International is a global leader in IV solutions, clinical nutrition, and medical devices. While not directly competing in Pakistan at Otsuka's scale, it represents the global incumbent in IV solutions and clinical nutrition that defines the category standards Otsuka Pakistan competes within at the global product level.
• Fresenius Kabi: Fresenius Kabi is a global leader in clinical nutrition, IV solutions, and infusion therapy. As a broad incumbent in clinical nutrition (enteral and parenteral), it represents the global category leader whose product concepts and quality benchmarks Otsuka Pakistan's nutrition portfolio competes against in international comparisons.

Direct peers

• Bayer Pakistan: Bayer Pakistan operates in pharmaceuticals and consumer health, with cardiology and radiology products. As a comparable foreign subsidiary on PSX, it competes in cardiovascular and therapeutic drug segments where Otsuka Pakistan's Pletaal operates, and shares the hospital-channel GTM model.
• The Searle Company: The Searle Company is a major Pakistani pharmaceutical manufacturer with diversified therapeutic and consumer health portfolio. Listed on PSX, it competes directly with Otsuka Pakistan in cardiovascular, gastrointestinal, and hospital-channel therapeutic segments.
• Ferozsons Laboratories: Ferozsons Laboratories is a leading Pakistani pharmaceutical manufacturer with strong hepatitis and oncology portfolios. Listed on PSX, it is directly comparable as a domestic pharma manufacturer competing in hospital-channel therapeutic segments alongside Otsuka Pakistan.
• AGP Limited: AGP Limited is one of Pakistan's largest pharmaceutical manufacturers with extensive IV solutions, generics, and consumer health portfolios. As a leading domestic player in IV solutions, it is one of the closest direct competitors to Otsuka Pakistan's core IV solutions business.
• Abbott Laboratories Pakistan: Abbott Pakistan manufactures and markets pharmaceuticals, nutritional products, and diagnostics in Pakistan. Its nutritional and IV solutions business directly overlaps with Otsuka Pakistan's clinical nutrition and IV solutions portfolio, both targeting hospital channels and patient nutrition segments.
• Sanofi Pakistan: Sanofi Pakistan is a multinational pharmaceutical manufacturer with operations across therapeutic categories including specialty care, vaccines, and consumer health. As another foreign-owned pharma subsidiary on PSX, it competes directly with Otsuka Pakistan in therapeutic drugs and IV/clinical nutrition across Pakistani hospitals and clinics.
• GlaxoSmithKline Pakistan: GSK Pakistan is a leading multinational pharmaceutical and consumer healthcare company listed on PSX. It directly competes with Otsuka Pakistan in therapeutic drugs, hospital-channel sales, and is a comparable foreign-subsidiary pharma entity targeting Pakistan's prescribing clinicians.
• Pfizer Pakistan: Pfizer Pakistan operates as a multinational pharma subsidiary marketing therapeutic drugs and hospital products. It competes with Otsuka Pakistan in cardiovascular (Pletaal area), gastroenterology (Mucosta area), and IV therapy segments within Pakistan's hospital and clinic channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@oplit2001
• Facebookfacebook.com/people/Otsuka-Pakistan-Ltd/61553986966106
• LinkedInlinkedin.com/company/otsuka-pakistan-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Pakistan